YOLT-204 for sickle cell disease and thalassemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is testing an experimental treatment called YOLT-204 for people with sickle cell disease (SCD) or beta-thalassemia. The goal is to see if YOLT-204 is safe and effective, potentially reducing the need for blood transfusions and improving symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 35 years old.
- You must have been diagnosed with either sickle cell disease or beta-thalassemia.
- You need to be eligible for blood transfusions and have medical records of your transfusions from the past two years.
- You must be willing to use contraception during the study and for a period after.
- You must be able to commit to regular hospital visits and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called YOLT-204 for young people with sickle cell disease. It aims to see if the drug can reduce severe pain episodes and other serious complications.
This study tests an experimental drug called YOLT-204 to see if it is safe and can help people with transfusion-dependent beta-thalassemia need fewer blood transfusions. It is for adults aged 18 to 35 who have a specific type of thalassemia and are otherwise healthy enough for the trial.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
Hear when a new Hemoglobinopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.